Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prospective cohort study of safety and immunogenicity of inactivated and viral vector COVID-19 vaccines in Thai adults
TCTR20210319003Completed
- Sponsor
- National Research Council Canada
- Start
- Mar 2021
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Open-label trial of BBIBP-CorV in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by National Research Council Canada. Primary endpoints: Safety outcomes and Immunogenicity outcomes. Started Mar 2021; status: completed.
02
Drugs
BBIBP-CorV
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on TCTR20210319003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20210319003.